Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 09/19/2024 at 07:05, 2 months 2 days ago

Newron Pharmaceuticals Presents H1 2024 Results and Business Update

Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
PRESS RELEASE

published on 09/19/2024 at 07:00, 2 months 2 days ago

Newron presents H1 2024 results and provides business update
Newron Pharmaceuticals presents H1 2024 financial results and operational highlights, focusing on evenamide studies for schizophrenia treatment and corporate developments

Financial Results Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
BRIEF

published on 06/25/2024 at 17:50, 4 months 25 days ago

Newron Pharmaceuticals Highlights 2024 Investor Day in NYC

Investor Day Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/25/2024 at 17:45, 4 months 25 days ago

Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City, highlighting evenamide's potential in treating treatment-resistant schizophrenia. Leading experts present clinical data and benefits of evenamide

Clinical Data Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide
BRIEF

published on 06/18/2024 at 17:50, 5 months 2 days ago

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

Investor Day Clinical Research Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/18/2024 at 17:45, 5 months 2 days ago

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City. Key opinion leaders to review findings on evenamide program for treatment-resistant schizophrenia

Investor Day Neuroscience Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 06/05/2024 at 17:50, 5 months 15 days ago

Newron Pharmaceuticals to Host 2024 Investor Day in New York City

Investor Day New York City Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/05/2024 at 17:45, 5 months 15 days ago

Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
Newron Pharmaceuticals announces 2024 Investor Day in New York City focusing on evenamide for treatment-resistant schizophrenia. Leading experts to present new findings

Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide Neurobiology
BRIEF

published on 05/13/2024 at 07:05, 6 months 8 days ago

Newron Pharmaceuticals Announces Positive Results for Evenamide in Schizophrenia Study

Clinical Study Schizophrenia Newron Pharmaceuticals Evenamide Mental Health Treatment
PRESS RELEASE

published on 05/13/2024 at 07:00, 6 months 8 days ago

Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Newron Pharmaceuticals S.p.A. presents compelling additional data from study 008A showcasing the efficacy of evenamide in poorly responding schizophrenia patients. Significant multi-domain benefits observed in PANSS and CGI-C ratings

Clinical Trial Study Results Newron Pharmaceuticals Evenamide Schizophrenia Patients

1 2 ... 4

Accesswire

Published on 11/21/2024 at 10:03, 27 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 30 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 30 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 55 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 5 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 25 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 28 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 30 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 30 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 29 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 32 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 10 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 45 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 45 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE